Alzheimer’s Disease and Brain Health: Expanding the Conversation

By: Dr. Sue Paul, Sr. Dir. Well-being & Brain Health, Asbury Communities, Inc.

I recently had the opportunity to sit down with neuroscientist Michael Yassa, PhD with the University of California, Irvine, to talk about brain health and Alzheimer’s disease. Like many public conversations, ours began with familiar territory. We discussed plaques, tangles, and the biology of the disease.

But what stayed with me most was where the conversation broadened.

Not instead of amyloid and tau, but alongside them.

Beyond Pathology Alone

One theme that surfaced was timing.

Alzheimer’s does not begin the day someone forgets a name. Biological changes can unfold for years, even decades, before symptoms become visible. That reality naturally shifts the focus upstream.

We talked about chronic stress, sleep disruption, metabolic health, physical inactivity, and social isolation. These are not fringe ideas. They are well-established influences on cognitive resilience.

The question is not whether lifestyle matters, but whether we treat it as a core priority.

At some point, prevention through daily conditions such as movement, restoration, vascular health, and cognitive engagement stops being an add-on and starts looking foundational.

The Ethics of Early Detection

Another important thread was early detection.

We are getting closer to identifying biological markers of Alzheimer’s risk long before clinical symptoms appear. That scientific progress is remarkable.

But it raises a very human question. Are we ready to know?

What does it mean for someone in midlife to learn they carry elevated risk? The answer depends heavily on whether that knowledge is paired with actionable guidance. Early detection without direction can create anxiety. Early detection with clear strategies can create agency.

The science is advancing quickly. Our ethical and psychological frameworks need to keep pace.

Measuring Brain Health Differently

We also explored whether brain health might eventually be monitored the way cardiovascular health is today.

In heart medicine, we track blood pressure and cholesterol long before the crisis. A similar shift may be emerging in neurology, with tools that measure subtle changes in cognitive resilience, digital performance patterns, or blood-based biomarkers.

The goal would not be labeling.

It would be feedback early enough to matter.

Prevention or Reframing

When I asked whether we would ever fully prevent Alzheimer’s, the answer was thoughtful and measured. Complex age-related diseases rarely yield to single solutions.

History offers perspectives. Heart disease was once considered an inevitable consequence of aging. Over time, layered strategies including medication, lifestyle modification, early screening, and public health changes altered outcomes significantly.

Perhaps Alzheimer’s will follow a similar path. Not eradicated overnight, but delayed, mitigated, and compressed.

That kind of progress is not dramatic.

It is meaningful.

Real Hope

What I appreciated most in our discussion was the absence of hype.

Hope in this field is built on earlier biological insight, better measurement, and a growing understanding that brain health is dynamic and influenced over decades.

We are still unraveling the mechanisms of disease.

But we are no longer ignoring the conditions in which those mechanisms unfold.

That feels like real progress.